|
|
||||||||





*
Program in Biomedical Sciences, Hood College, and
Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
The Yersinia adherence molecule invasin binds to ß integrins on the surface of a variety of cells. The interaction of ß integrin with invasin is required for Yersinia to attach to mammalian cells and promotes cellular internalization (5). However, contact with the mammalian cell membrane stimulates the expression and cytoplasmic translocation of Yersinia outer proteins (Yops)3 into the cytosol to block phagocytosis (6). The activity of YopH, a protein-tyrosine phosphatase, prevents transduction of a cellular internalization signaling event (6, 7, 8, 9), YopE indirectly disrupts filamentous actin polymerization (6), and YpkA, a serine/threonine kinase (10), may interfere with signal transduction.
Yops are encoded by a plasmid that is homologous in all pathogenic Yersinia. However, Y. pestis does not synthesize either invasin or YadA, another adhesin produced by Y. enterocolitica and Y. pseudotuberculosis. Consequently, no established adhesin has been described for Y. pestis, although the pH 6 Ag has been suggested to play such a role (11). Translocation of Yops by Y. pestis in cultured mammalian cells required introduction of YadA in some reports (8), while the results of another study (12) showed translocation by unmodified Y. pestis. Thus, it remains unclear whether cytosolic delivery of Yops occurs in vivo during Y. pestis infection. An IS200-like element inserted into the chromosomal gene (13) results in defective expression of invasin by Y. pestis. Infection with enteropathogenic Yersinia initiates class I-dependent CTL responses (14). It remains a possibility that the host immune response to Y. pestis may be deficient without the immune stimulation provided by adherence to cellular substratum and cytosolic delivery of bacterial Ags. Adhesin-independent infections may promote systemic dissemination by preventing CTL-mediated control of primary foci. To test this possibility, we used a genetic vaccine, consisting of sequences encoding the fraction 1 (F1) capsule Ag, to simulate cytosolic insertion of pathogen-derived Ags and examined Ab and T cell immunity resulting from intracellular expression of Y. pestis proteins.
| Materials and Methods |
|---|
|
|
|---|
Recombinant F1 polypeptide (rF1) was prepared as previously
described (15). Endotoxin was removed by passing rF1 over a column of
immobilized polymyxin B (Detoxi-Gel, Pierce, Rockfort, IL) as
previously described (15). The F1 gene was isolated from a genomic
clone of the caf operon (16) using PCR and synthetic
oligonucleotides of sequences flanking the gene. The plasmid pREF1 was
made by ligating the F1-coding fragment into the mammalian cell
expression vector pREP4 (Invitrogen, Carlsbad, CA) downstream of a Rous
sarcoma virus promoter. A hygromycin resistance gene is also contained
within pREF1. Plasmids were propagated in Escherichia coli
strain DH5
(Invitrogen) and were isolated by alkaline lysis,
followed by anion exchange chromatography (Qiagen, Valencia, CA).
Plasmids were dialyzed extensively against PBS (pH 7.4) to remove
residual endotoxin. The final preparations of plasmid or rF1 contained
<1 U of endotoxin/injection, as determined by a Limulus
lysate assay (BioWhittaker, Walkersville, MD).
Cell lines
The mouse cell line P815 was obtained from American Type Culture Collection (Manassas, VA). Cells that constitutively expressed the F1 polypeptide were produced by transfecting P815 with pREF1 and selecting stably transformed cells by hygromycin resistance using methods previously described (17). Plasmid DNA (5 µg) was mixed with 15 µl of Lipofectin (Life Sciences, Gaithersburg, MD) in 200 µl of serum-free medium (Eagles MEM) and added to the cells for 12 h (37°C, CO2 incubator). The transfected cells were subcultured into 4 ml of Eagles MEM containing 5% FBS and 400 U/ml of hygromycin (Calbiochem, San Diego, CA). Colonies appearing in 10 to 14 days were maintained in culture medium containing hygromycin (400 U/ml).
Immunizations
Female BALB/c mice (4 mo old; Harlan Sprague-Dawley, Frederick, MD) were injected i.m. (rectus femoris muscle) with 10 µg of pREF1, plasmid without gene insert (pREP9) in 50 µl of PBS (50 mM Na2HPO4 and 140 mM NaCl, pH 7.4), or with 10 µg of purified rF1 in PBS resuspended in alhydrogel adjuvant (E. M. Sergeant Co., Nutley, NJ). A total of three injections were given, 2 wk apart, unless indicated otherwise. Sera were collected from tail veins for Ab analyses before and 1 wk after each injection.
In conducting research using animals, the investigators adhered to the Guide for the Care and Use of Laboratory Animals, prepared by the committee on care and use of laboratory animals of the Institute of Laboratory Animal Resources, National Research Council.
Ab assays
Purified rF1 (1 µg/well in 100 µl of PBS) was used to coat the wells (37°C, 2 h) of 96-well plastic plates (Immulon, San Francisco, CA). The plates were then blocked (37°C, 4 h) with 100 µl of 0.2% casein in PBS and washed with PBS containing 0.1% Tween-20 (Sigma, St. Louis, MO). Preimmune or immune mouse sera were diluted in PBS containing 0.02% casein, and 100 µl of each dilution was added to duplicate wells (37°C, 2 h). The plates were washed with PBS and incubated (37°C, 1 h) with a 1/2000 dilution of peroxidase-conjugated goat anti-mouse Ab (Pierce). The plates were washed, and 100 µl of ABTS (Kirkegaard Perry, Gaithersburg, MD) was added. After 20 min, 100 µl of 1% SDS was added to stop the reaction. Peroxidase levels were detected by measuring the absorbance at 405 nm.
Bacterial challenges
Immunized and control mice were administered 400 to 800 x LD50 of Y. pestis CO92 (LD50 = 2.3 x 104 CFU) by nasal aerosol, as previously described (15). All infected animals were monitored daily until 28 days postchallenge.
Generation of effector T cells
Spleens were removed from mice, and mononuclear cell preparations were prepared as previously described (18). The mononuclear cells (5 x 106/well) were cultured with syngeneic dendritic cells (5 x 105/well), obtained as previously described (18), in 24-well plates containing a 20 µg/ml final concentration of purified rF1. Culture medium consisted of RPMI 1640 supplemented with 10% FCS, 2 mM glutamine, 10 µM HEPES, 50 µM 2-ME, 100 IU/ml penicillin, and 100 µg/ml streptomycin. The mononuclear cell cultures were harvested after 5 days of incubation (37°C, 5% CO2/95% humid air) for lymphocyte cytotoxicity assays.
Cytolytic T cell assay
To measure Ag-specific CTL activity, 4-h 51Cr release assays were performed. Briefly, target cells were labeled with 300 µCi of 51CrO4Na2 (Amersham, Arlington Heights, IL) for 90 min before assay. The 51Cr-labeled target cells (1 x 104 in 100 µl) were washed, resuspended (2 x 105/ml), and added to 96-well U-bottom plates. Mononuclear effector cells were added, and the wells were incubated for 4 h. Supernatant fluids (200 µl) were harvested and measured in a radiation counter. Percent specific lysis was calculated as follows: 100 x [(experimental release - spontaneous release)/(maximum release - spontaneous release)].
Values for lysis of untreated cells were subtracted to obtain specific lysis. Spontaneous release was determined by incubating 51Cr-labeled target cells in medium alone, and maximum release was determined by incubating cells in 1% SDS. Assays were performed in triplicate wells. Spontaneous release of 51Cr from target cells for data shown was <15%.
Cytokine analysis
IFN-
was measured by a commercially available kit (Genzyme,
Cambridge, MA), according to the manufacturers instructions.
Mononuclear cells from vaccinated and control mice were collected as
described above and cultured (7 days, 37°C, 5% CO2) with
rF1 (1050 µg/ml) in 24-well cell culture plates. Culture
supernatants (300 µl) were used for cytokine analyses.
Ab isotyping
Mouse serum Abs were isotyped by using a commercially available kit (Bio-Rad, Richmond, CA). The rF1 (1 µg/well) was adsorbed onto 96-well Immulon plates (30 min, 37°C), then washed with PBS. The wells were washed with PBS, blocked with 1% BSA in PBS (22°C, 30 min), and washed with PBS containing 0.2% Tween-20 (Sigma). Dilutions (1/100) of mouse sera were added, and plates were incubated for 30 min (37°C) and washed. Rabbit anti-mouse Ig (isotype specific) were added (100 µl) to the appropriate wells (37°C, 30 min), the plates were washed with PBS, and peroxidase-conjugated goat anti-rabbit was added (1/2000 dilution, 30 min, 37°C). The plates were washed with PBS to remove unbound reagents, and chromogenic substrate (2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS)) was added. Absorbance (405 nm) was measured after a 20-min incubation.
| Results |
|---|
|
|
|---|
The F1 Ag is encoded within an operon of a 100-kb plasmid (19)
that includes accessory gene products required for optimal expression
of the F1 Ag in bacteria. The F1 polypeptide forms a high molecular
mass aggregate (>300 kDa; data not shown) when expressed in E.
coli or mammalian cells. No detectable F1 was released into the
culture medium, suggesting that most of the Ag remained within the
transfected cells. Mice (BALB/c) were injected i.m. with pREF1 in PBS
or with purified rF1 adsorbed to alhydrogel. Serum Ab titers were
measured 1 wk after each of three injections. Significant Ab responses
were apparent for both plasmid and recombinant polypeptide injections
(Fig. 1
, A and B).
However, the maximum levels of Ab elicited by rF1 immunizations were
greater than those obtained with plasmid (Fig. 1
, A
and B). The genetic vaccination provided no protection from
high dose challenges (400800 LD50) with live bacteria,
whereas mice injected with rF1 were protected (Fig. 2
). Because it was possible that the
plasmid was not efficiently taken up by the appropriate APCs, we also
injected mice with plasmid encapsulated in cationic liposomes. The
circulating Ab levels of animals that received plasmid in liposomes
were equivalent to those obtained from mice injected with plasmid in
buffer (Fig. 3
).
|
|
|
|
Ab responses were consistently obtained only from inbred mice
immunized with pREF1. However, these responses were always less than
those obtained from rF1 immunizations. It was conceivable that
differences in the magnitude of the immune response to plasmid compared
with that to rF1 were related to the introduction of the Ag into an
intracellular compartment that circumvented efficient T cell priming of
Ab responses. To examine this possibility more closely, BALB/c and
Swiss-Webster mice were injected with 10 µg of pREF1 followed by one
injection of 10 µg of rF1 2 mo later. Serum samples were collected at
1 and 3 wk following the polypeptide injection. With BALB/c mice, serum
Ab titers were equal to or greater than those obtained from mice that
had received three injections of recombinant polypeptide (Fig. 5
A). These results suggested
that BALB/c mice generated a vigorous primary response to
plasmid-expressed F1. In contrast, immunization of Swiss-Webster mice
with pREF1 did not produce an anamnestic response to rF1 (Figs. 4
and 5
B). The Ab level induced by pREF1 priming and rF1 boost of
outbred mice was less than or equal to the Ab response obtained from
BALB/c mice by a single injection of rF1 (Fig. 5
B). Because
three injections of pREF1 in Swiss-Webster mice produced little or no
Ab response (Fig. 4
), these data confirmed that the outbred mice did
not respond to F1 when plasmid was used for immunization.
|
Our data indicated that the relative magnitude of the Ab response
to plasmid-expressed F1 varied little between inbred mouse strains. We
further dissected the immune response to F1 to detect any potential
differences among mouse strains. Based on Ab isotype ratios
(IgG2a:IgG1), plasmid-injected BALB/c mice had a greater Th1 propensity
than mice immunized with rF1 (Fig. 6
). In
contrast, mice that were primed with pREF1 and boosted with rF1
exhibited a predominant Th2 response, similar to mice that had received
three injections of rF1. The control plasmid also induced detectable
levels of background Th1-like Abs, perhaps as a result of responses to
CpG motifs within the bacterial DNA (20).
|
when the mice were
immunized with rF1, and only H-2d and H-2s mice
that were immunized with plasmid-expressed F1 appeared to secrete
levels of IFN in vitro that were greater than those in controls (Fig. 7
|
The Ab response to rF1 was presumably mediated by an endocytic,
MHC class II-dependent route of presentation. By the same reasoning,
the endogenous expression of Ag from pREF1 may be more effective in
inducing CTL responses. To test this, P815 cells that stably expressed
F1 from the transfected pREF1 vector were 51Cr labeled and
used for targets. Lymphocytes for the CTL assays were obtained from
spleens of BALB/c mice 12 wk after the last immunization. Although
there was a greater level of CTL recognition of F1 resulting from
cytosolic expression of the Ag (pREF1 immunization) compared with that
after rF1 immunization, the responses were weak in general (Table I
).
|
We examined serum F1-specific Ab levels of immunized mice at 2-wk
intervals after the last injection. There was a slight decrease in Ab
titers with extended time for mice immunized with pREF1 alone (Fig. 8
). However, when mice were immunized
with either rF1 alone or pREF1 followed by a boost with rF1, Ab titers
stayed consistently high over the time intervals examined (Fig. 8
).
These results indicated that primary or secondary immunization by an
exogenous route was necessary to maintain long lived Ab responses.
|
| Discussion |
|---|
|
|
|---|
Details concerning the initiation of Y. pestis infections
are not well understood. Enteropathogenic Yersinia bind
specifically to ß1 integrin on the basolateral membrane
of intestinal epithelial cells by means of the inv gene
product invasin (5). Breaches in intercellular tight junctions caused
by transepithelial migration of inflammatory neutrophils may allow
transient access to these ß integrin binding sites (23) and
subsequent tissue invasion. Moreover, host immune responses to all
Yersinia are restricted by a complex interplay of bacterial
virulence factors that also control the development of lesions. The
secreted V protein (24) and perhaps other Lcr plasmid-encoded products,
such as YopB (25), may suppress the release of the proinflammatory
cytokines TNF-
and IFN
, while YopE is a contact-dependent
cytotoxin (8). A potential superantigen has also been described for
some strains of Y. pseudotuberculosis (26).
Vaccinations with the soluble V protein (27) or the capsular F1 Ag (15)
provide protection from the most virulent strains of Y.
pestis. Abs against the V polypeptide are postulated to neutralize
the inhibition of TNF-
and IFN-
secretion (28), thus restoring
immune effector functions. Based on our results and previous reports
(15), Ab neutralization is the most likely mechanism of protection
induced by vaccination with recombinant F1 polypeptide. Although high
levels of F1 polypeptide are expressed intracellularly, no detectable
amounts of Ag are released extracellularly from transfected cells
(our unpublished observations). However, significant Ab titers
resulted from genetic immunization, suggesting that the cells that were
initially transfected with plasmid were responsible in vivo for
stimulating F1-specific Ab responses, and that Ag taken up by secondary
APCs may be less important. Previous studies indicate that dendritic
cells have a key role in presenting Ags from genetic immunizations in
mice,4 and thus may be the
primary APCs that were transfected with the F1 plasmid.
It was noteworthy that the maximum Ab levels obtained from intracellular targeting of the F1 Ag were 3 times less than those resulting from immunizations with polypeptide in adjuvant. Perhaps a careful study of immunization schedules may improve these results. It is also possible that internalization and endosomal transport of the polypeptide are critical for stimulating optimal Ab responses, and that intracellular expression of F1 results in a dominant MHC class I-associated presentation pathway. Alternatively, the induction of lower Ab levels may have resulted from the shift from a Th2 response, induced by polypeptide immunization, to a more Th1-like response to plasmid-expressed Ag. In addition, MHC class II-dependent Th cell activity may support the CTL responses to transfected F1, especially if the Ag is more limited in concentration than that resulting from injections of the recombinant polypeptide (29). Our results also suggest that a Th2-induced Ab response is more efficacious for immune protection against Y. pestis in mice.
All the homozygous H-2 mouse strains that were immunized with the F1
expression plasmid responded at roughly equivalent Ab levels, whereas
no primary or secondary Ab stimulation was detected in the outbred
Swiss-Webster mice. Although this phenomenon may be specific to the F1
Ag, no similar comparisons of outbred and inbred mouse responses to
genetic vaccines have been reported. There was also considerable
variability among the homozygous H-2 strains tested in secondary in
vitro cytokine responses to F1. Previous studies postulated that mouse
resistance to Y. enterocolitica is multigenic and is not
controlled exclusively by H-2 loci (30) but depends on the production
of IFN-
(31). Recognition of endogenous peptides by CTLs is
generally limited to Ags that bypass endosomes (32). Preliminary data
suggest that CTL responses to F1 also vary for mice of differing H-2
background (our unpublished observations). Collectively, these
results suggest that caution should be used in interpreting genetic
immunization studies that rely only on data obtained from one strain of
mice.
Finally, our results suggest a useful immunization strategy that combines the traditional polypeptide vaccine with an Ag expression plasmid. Following a primary injection with either plasmid or F1 polypeptide, all inbred mouse strains responded with equivalent Ab levels to a secondary stimulation by recombinant polypeptide. Because CTL activity was also generated by the genetic vaccine, and optimal Ab responses resulted from a boost with polypeptide in adjuvant, a combination plasmid/polypeptide vaccine approach may optimally promote both humoral and cellular mechanisms of immunity to Yersinia.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Robert G. Ulrich, Laboratory of Molecular Immunology, Army Medical Research Institute of Infectious Diseases, 1425 Porter St., Frederick, MD 21702. E-mail address: ![]()
3 Abbreviations used in paper: Yops, Yersinia outer proteins; F1, fraction 1 capsular protein; rF1, recombinant F1 polypeptide; pREF1, F1 mammalian-expression plasmid; LD50, dose causing 50% mortality. ![]()
4 K. U. Saikh and R. G. Ulrich. Dendritic cells present the products of a tetanus toxin DNA vaccine and stimulate primary antibody and cytotoxic T-cell responses. Submitted for publication. ![]()
Received for publication February 2, 1998. Accepted for publication June 22, 1998.
| References |
|---|
|
|
|---|
interferon and tumor necrosis factor
. Infect. Immun. 61:23.
expression. Infect. Immun. 63:1270.[Abstract]
interferon. Infect. Immun. 62:2590.This article has been cited by other articles:
![]() |
H. Yamanaka, T. Hoyt, X. Yang, S. Golden, C. M. Bosio, K. Crist, T. Becker, M. Maddaloni, and D. W. Pascual A Nasal Interleukin-12 DNA Vaccine Coexpressing Yersinia pestis F1-V Fusion Protein Confers Protection against Pneumonic Plague Infect. Immun., October 1, 2008; 76(10): 4564 - 4573. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. U. Saikh, T. L. Kissner, A. Sultana, G. Ruthel, and R. G. Ulrich Human Monocytes Infected with Yersinia pestis Express Cell Surface TLR9 and Differentiate into Dendritic Cells J. Immunol., December 15, 2004; 173(12): 7426 - 7434. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Swietnicki, S. O'Brien, K. Holman, S. Cherry, E. Brueggemann, J. E. Tropea, H. B. Hines, D. S. Waugh, and R. G. Ulrich Novel Protein-Protein Interactions of the Yersinia pestis Type III Secretion System Elucidated with a Matrix Analysis by Surface Plasmon Resonance and Mass Spectrometry J. Biol. Chem., September 10, 2004; 279(37): 38693 - 38700. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Grosfeld, S. Cohen, T. Bino, Y. Flashner, R. Ber, E. Mamroud, C. Kronman, A. Shafferman, and B. Velan Effective Protective Immunity to Yersinia pestis Infection Conferred by DNA Vaccine Coding for Derivatives of the F1 Capsular Antigen Infect. Immun., January 1, 2003; 71(1): 374 - 383. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |